{"gene":"SDHB","run_date":"2026-06-10T07:46:30","timeline":{"discoveries":[{"year":2001,"finding":"Inactivating germline SDHB mutations cause loss of complex II catalytic activity, establishing SDHB as part of the catalytic core of succinate dehydrogenase (mitochondrial complex II) and a tumor suppressor gene whose disruption predisposes to pheochromocytoma and paraganglioma.","method":"Mutation analysis (sequencing) of familial pheochromocytoma kindreds; functional context from known complex II biochemistry","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mutation identification in familial cases with biochemical context; single study but clear loss-of-function result","pmids":["11404820"],"is_preprint":false},{"year":2002,"finding":"A germline SDHB missense mutation combined with somatic loss of heterozygosity at 1p36 (SDHB locus) resulted in complete loss of mitochondrial complex II enzymatic activity in a pheochromocytoma, accompanied by upregulation of hypoxia-angiogenic responsive genes (pseudohypoxia), demonstrating that biallelic SDHB inactivation abolishes complex II function and activates the hypoxic/angiogenic pathway.","method":"LOH analysis, respiratory chain enzyme assay, in situ hybridization, immunohistochemistry on tumor tissue","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct enzyme activity assay confirming complete loss of complex II activity, combined with LOH analysis and IHC/ISH for pathway activation; single lab but multiple orthogonal methods","pmids":["12364472"],"is_preprint":false},{"year":2003,"finding":"Deleterious SDHB germline mutations in pheochromocytoma are associated with complete loss of complex II catalytic activity in tumor tissue and LOH at chromosome 1p36 (SDHB locus), confirming SDHB as a tumor suppressor following a two-hit mechanism.","method":"Respiratory chain enzyme assay, LOH analysis, immunohistochemistry on tumor samples","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct enzyme activity assays combined with LOH and IHC; replicated findings from prior work with larger cohort","pmids":["14500403"],"is_preprint":false},{"year":2008,"finding":"SDHB silencing by DNA-based siRNA impaired cellular respiration, caused a shift to glycolysis, upregulated HIF-1α and HIF-2α (pseudohypoxia), hyperphosphorylated JNK and p38 stress kinases, and increased cell adhesion to extracellular matrix components (fibronectin, laminin); partial reversal of the adhesion phenotype by transient HIF-1α silencing implicated HIF-1 in this process.","method":"RNA interference (siRNA knockdown), respirometry, microarray, Western blot, cell adhesion assay, transient HIF-1α knockdown","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KD with multiple orthogonal readouts (respiration, ROS, gene expression, adhesion, rescue experiment); single lab","pmids":["18519664"],"is_preprint":false},{"year":2009,"finding":"SDHB protein expression is absent by immunohistochemistry in tumors harboring SDHB, SDHC, or SDHD mutations but is retained in tumors from MEN2, VHL, and NF1 patients, demonstrating that loss of any SDH subunit destabilizes the whole complex including the SDHB subunit, making SDHB IHC a surrogate marker for SDH complex integrity.","method":"Immunohistochemistry on 220 tumors with known mutation status (retrospective and prospective series)","journal":"The Lancet. Oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — large prospective and retrospective series with known mutation status; independently replicated across multiple cohorts","pmids":["19576851"],"is_preprint":false},{"year":2012,"finding":"Common SDHB missense mutations do not impair mRNA expression or intrinsic enzymatic function, but reduce protein half-life (accelerated degradation), demonstrated by pulse-chase assay; the mutant SDHB protein retains correct mitochondrial localization and the ability to co-immunoprecipitate with SDHA, indicating complex formation is intact. Treatment with HDAC inhibitors extended mutant protein half-life, implicating the protein quality control machinery in SDHB degradation.","method":"Pulse-chase assay in transfected HeLa cells, RT-PCR, Western blot, subcellular colocalization, co-immunoprecipitation, HDAC inhibitor treatment","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reconstitution-type in vitro pulse-chase with mutagenesis context, co-IP and colocalization, pharmacological rescue; single lab but multiple orthogonal methods","pmids":["22835832"],"is_preprint":false},{"year":2012,"finding":"SDHB mutations are associated with activation of epithelial-to-mesenchymal transition (EMT) in metastatic pheochromocytomas/paragangliomas, evidenced by upregulation of LOXL2, TWIST, TCF3, MMP2, MMP1 and downregulation of KRT19 and CDH2, with nuclear translocation of Snail1/2 specifically in SDHB-mutated metastatic tumors.","method":"Transcriptomic profiling of 188 tumor samples (94-gene EMT panel), immunohistochemistry (Snail1/2) in 93 tumors","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — large transcriptomic dataset with IHC validation; single lab, correlative rather than experimental manipulation of SDHB","pmids":["22492777"],"is_preprint":false},{"year":2012,"finding":"Homozygous SDHB mutation (p.Asp48Val) in a patient causes severe isolated mitochondrial complex II deficiency with hypotonia and leukodystrophy; Western blot and BN-PAGE confirmed decreased steady-state SDHB protein and impaired complex II assembly; yeast complementation studies confirmed pathogenicity.","method":"Western blot, BN-PAGE, enzyme activity assay, yeast complementation","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct enzyme activity, protein assembly assays, and yeast complementation functional validation; single report but multiple orthogonal methods","pmids":["22972948"],"is_preprint":false},{"year":2015,"finding":"In Sdhb-knockout mouse chromaffin cells, loss of SDHB produced increased individual cell migration (faster motility, increased persistence), invasiveness, and adhesion; this phenotype was associated with epigenetic silencing (hypermethylation) of Krt19 and EMT-like reprogramming (modulation of Twist1, Twist2, Tcf3, Snai1, N-cadherin). KRT19 rescue by lentiviral transduction reduced invasion, and KRT19 knockdown in wild-type cells increased invasion, establishing KRT19 as a downstream effector of SDHB loss-driven invasiveness.","method":"Sdhb knockout in mouse chromaffin cells, migration/invasion assays, lentiviral KRT19 rescue, siRNA KRT19 knockdown, bisulfite sequencing, demethylating agent treatment","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO model with functional rescue and knockdown experiments using multiple orthogonal methods; single lab","pmids":["26460615"],"is_preprint":false},{"year":2015,"finding":"SDHB silencing in PC12 pheochromocytoma cells abolishes complex II activity, increases ROS production and stabilizes nuclear HIF1α under normoxia; these effects increase tyrosine hydroxylase activity and catecholamine secretion. Pretreatment with NAC (ROS scavenger) or HIF1α knockdown abolishes these phenotypes, establishing an ROS→HIF1α→catecholamine axis downstream of SDHB loss.","method":"siRNA knockdown in PC12 cells, complex II activity assay, ROS measurement, catecholamine secretion assay, NAC treatment, HIF1α siRNA rescue","journal":"Neurochemical research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — enzymatic assay + ROS measurement + pharmacological and genetic rescue experiments; single lab but multiple orthogonal methods","pmids":["26620190"],"is_preprint":false},{"year":2016,"finding":"The SDHB R46Q mutation in an SDHB-deficient renal cell carcinoma line (UOK269) disrupts binding of the cochaperone HSC20 to the L(I)YR Fe-S transfer motif in SDHB, causing rapid SDHB degradation and loss of SDH activity. In the absence of SDHB, succinate accumulates (351.4 ± 63.2 nmol/mg), respiration is undetectable, glutamine becomes the main TCA substrate via reductive carboxylation, HIF1α (not HIF2α) increases, and a CpG island methylator phenotype (CIMP) develops. Bioinformatic screening showed 37% of disease-causing SDHB missense mutations affect LYR Fe-S transfer motifs or Fe-S cluster-ligating cysteines.","method":"Stable isotope-resolved metabolomics, biochemical co-chaperone binding assay, respiration assay, Western blot, bioinformatics in novel SDHB-deficient RCC cell line","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reconstitution-level metabolomics and biochemical assays in a defined SDHB-null cell line, with Fe-S chaperone binding mechanism identified; single lab but multiple orthogonal methods","pmids":["26719882"],"is_preprint":false},{"year":2013,"finding":"SDHB mRNA undergoes C-to-U coding RNA editing (C136U, R46X) in peripheral blood monocytes; this editing is markedly upregulated by hypoxia (1% O2) and during macrophage differentiation, representing an epigenetic post-transcriptional mechanism that downregulates SDHB function in monocytes during hypoxia adaptation. CD14-positive monocytes are the principal editing cell type; CD14-negative lymphocytes show no editing.","method":"Allele-specific quantitative PCR, flow cytometry, immunologic cell separation, gene expression microarray, high-throughput RNA sequencing, hypoxia exposure experiments","journal":"PeerJ","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel mechanism identified with multiple orthogonal methods (qPCR, RNA-seq, cell fractionation, hypoxia experiments); single lab","pmids":["24058882"],"is_preprint":false},{"year":2016,"finding":"SDHB deficiency in colorectal cancer cells promotes cell migration and invasion through EMT enabled by upregulation of the transcriptional repression complex SNAIL1-SMAD3/SMAD4, activating TGFβ signaling. SDHB knockdown increased migration/invasion, while SDHB overexpression reversed this; SNAIL1-SMAD3/SMAD4 was identified as the downstream mediator.","method":"siRNA knockdown, overexpression, transwell migration/invasion assays, Western blot, pathway analysis in colorectal cancer cells","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD and OE with reciprocal phenotype plus pathway identification; single lab","pmids":["27816688"],"is_preprint":false},{"year":2020,"finding":"TET2 loss (induced by low shear stress) upregulates SDHB expression and activity by decreasing recruitment of histone deacetylase 2 to the SDHB promoter (independent of DNA demethylation), leading to SDHB-mediated mitochondrial injury, increased ROS, and vascular endothelial cell pyroptosis; ROS scavenger NAC rescued pyroptosis, placing SDHB downstream of TET2 in a TET2/SDHB/ROS pathway.","method":"TET2 shRNA, SDHB overexpression, NAC treatment, HDAC2 recruitment assay, mitochondrial ROS measurement, pyroptosis assay in HUVECs","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological intervention with mechanistic epistasis; single lab","pmids":["33248263"],"is_preprint":false},{"year":2020,"finding":"SDHB overexpression in endothelial cells enhances pyroptosis and mitochondrial ROS production; this effect is blocked by the ROS scavenger NAC, establishing that SDHB-driven ROS mediates endothelial cell pyroptosis in the context of TMAO-induced atherosclerosis.","method":"SDHB overexpression in HUVECs, NAC treatment, ROS assay, pyroptosis assay, apoE-/- mouse model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with pharmacological rescue showing ROS dependence; single lab","pmids":["32012263"],"is_preprint":false},{"year":2021,"finding":"Loss of SDHB specifically (compared to SDHD loss) leads to dysregulated iron and copper homeostasis, increased oxidative stress, and hallmarks of mesenchymal transition associated with stronger DNA hypermethylation and pseudo-hypoxic phenotype, without NRF2 activation. High-dose ascorbate exacerbated mitochondrial ROS selectively in Sdhb-deficient cells, causing cell death, establishing a mechanistic link between SDHB loss, iron overload, and ROS accumulation distinct from SDHD loss.","method":"Sdhb and Sdhd knockout chromaffin cell lines, metabolic analysis, ROS assay, iron/copper homeostasis measurements, ascorbate treatment, comparative SDHB vs SDHD cell analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — comparative KO models with multiple metabolic and functional assays, pharmacological intervention; single lab but multiple orthogonal methods","pmids":["34127497"],"is_preprint":false},{"year":2022,"finding":"Mouse adrenal medulla-specific SDHB disruption recapitulates succinate accumulation but does NOT cause 5hmC loss, HIF accumulation, or tumorigenesis on its own. Concomitant SDHB and NF1 disruption yields SDHx-like pheochromocytomas, demonstrating that SDHB loss requires additional growth-regulatory pathway activation (NF1 loss) for tumorigenesis. In vitro, 2-OG dioxygenase cofactor ascorbate depletion reduces SDHB-deficient cell survival.","method":"Conditional mouse SDHB knockout, double SDHB/NF1 knockout mouse model, in vivo tumor analysis, ascorbate depletion cell survival assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis with double KO model plus in vitro mechanistic follow-up; single study but rigorous genetic approach with clear negative and positive results","pmids":["35235785"],"is_preprint":false},{"year":2021,"finding":"Loss of sdhb in zebrafish larvae (CRISPR/cas9 truncating mutation) decreases mitochondrial complex II activity and causes significant succinate accumulation, recapitulating the metabolic phenotype of human SDHB-associated paragangliomas in a vertebrate model.","method":"CRISPR/cas9 zebrafish knockout, complex II enzymatic activity assay, metabolomic analysis (succinate measurement), behavioral and morphological phenotyping","journal":"Endocrine-related cancer","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct enzymatic assay and metabolomics in an in vivo genetic model; single lab but multiple orthogonal methods","pmids":["33156815"],"is_preprint":false},{"year":2014,"finding":"SDHB germline mutations in metastatic pheochromocytoma/paraganglioma are associated with hypermethylation of the MGMT promoter and low MGMT expression, which correlates with responsiveness to temozolomide chemotherapy; partial responses to TMZ were observed only in SDHB-mutated patients.","method":"Retrospective clinical study, MGMT immunohistochemistry, MGMT promoter methylation analysis in 190 PPGLs, survival/response analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic link between SDHB mutation status and MGMT methylation established in large tumor cohort with clinical correlation; single study","pmids":["24752622"],"is_preprint":false},{"year":2019,"finding":"SDHB-deficient pheochromocytoma cells (with pseudohypoxia from SDHB loss) display elevated expression of iron transport proteins (transferrin, TFR2, DMT1/SLC11A2), leading to iron accumulation and elevated oxidative stress; pharmacological ascorbic acid disrupts redox homeostasis, induces DNA oxidative damage and apoptosis selectively in SDHB-low cells, and suppresses metastatic lesions in a mouse allograft model.","method":"Western blot for iron transport proteins, ROS/oxidative stress assays, ascorbic acid treatment in vitro and in vivo (mouse allograft model), survival analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanism linked to iron transport protein upregulation with in vitro and in vivo validation; single lab","pmids":["32152203"],"is_preprint":false},{"year":2018,"finding":"SDHB-deficient cluster I PCPGs develop dependency on mitochondrial complex I and enhanced NAD+ metabolism; this supports chemoresistance via the PARP1/BER DNA repair pathway. Combining a PARP inhibitor with temozolomide improved cytotoxicity, reduced metastatic lesions, and prolonged survival in mice with SDHB-knockdown PCPG allografts.","method":"Transcriptomic profiling of clinical specimens, PARP inhibitor + TMZ combination in vitro and in vivo (mouse allograft), NAD+ pathway analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway identification from clinical specimens with in vivo pharmacological validation; single lab","pmids":["29636359"],"is_preprint":false},{"year":2015,"finding":"Carney triad tumors and Sdhb+/- mouse gastrointestinal tissues share an identical mitochondrial structural phenotype (loss of cristae, structural abnormalities, variable size) with SDH-deficient tumors, establishing that SDHB haploinsufficiency is sufficient to produce abnormal mitochondrial morphology (hypoxic mitochondrial phenotype) in vivo.","method":"Electron microscopy of human tumors (CTr, CSS, isolated GIST) and Sdhb+/- mouse GI tissue","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ultrastructural comparison of genetic model with human tumor tissue; single study with clear morphological data","pmids":["25808178"],"is_preprint":false}],"current_model":"SDHB encodes the iron-sulfur subunit of mitochondrial complex II (succinate dehydrogenase); biallelic loss abolishes complex II enzymatic activity, causing succinate accumulation that inhibits 2-oxoglutarate-dependent dioxygenases (driving DNA/histone hypermethylation and pseudohypoxia via HIF stabilization), while disease-causing missense mutations primarily destabilize the protein by disrupting HSC20-mediated Fe-S cluster delivery or accelerating proteasomal degradation without intrinsically impairing enzymatic activity; downstream consequences of SDHB loss include ROS-mediated HIF1α stabilization, iron homeostasis dysregulation, EMT-like transcriptional reprogramming (via SNAIL1-SMAD3/4 and epigenetic KRT19 silencing), increased cell invasiveness and collective migration, and—requiring cooperative loss of additional tumor suppressors such as NF1—frank tumorigenesis."},"narrative":{"mechanistic_narrative":"SDHB encodes the iron-sulfur subunit of mitochondrial complex II (succinate dehydrogenase), and its inactivation defines a tumor-suppressor mechanism in which loss of complex II catalytic activity drives succinate accumulation and a pseudohypoxic transcriptional program [PMID:11404820, PMID:12364472, PMID:14500403]. Biallelic inactivation—a germline mutation plus somatic loss of heterozygosity at the 1p36 SDHB locus—abolishes complex II enzymatic activity and upregulates hypoxia-angiogenic responsive genes [PMID:12364472, PMID:14500403]. Loss of SDHB destabilizes the entire SDH complex such that the SDHB protein becomes undetectable by immunohistochemistry, making it a surrogate marker of complex integrity [PMID:19576851]. At the protein level, common disease-causing missense mutations do not impair intrinsic enzymatic function or complex assembly but accelerate proteasomal degradation, frequently by disrupting binding of the cochaperone HSC20 to the L(I)YR Fe-S transfer motif, thereby blocking iron-sulfur cluster delivery [PMID:22835832, PMID:26719882]. SDHB loss reprograms cell metabolism toward glycolysis and reductive glutamine carboxylation, raises mitochondrial ROS, and stabilizes HIF1α under normoxia, an axis that in chromaffin cells elevates catecholamine secretion [PMID:18519664, PMID:26620190, PMID:26719882]. Succinate accumulation and associated DNA/histone hypermethylation underlie a CpG island methylator phenotype, including epigenetic silencing of KRT19, and an EMT-like program—via nuclear Snail1/2 and a SNAIL1-SMAD3/4 repressor complex—that promotes invasion and migration [PMID:22492777, PMID:26460615, PMID:26719882, PMID:27816688]. SDHB loss also dysregulates iron and copper homeostasis, generating oxidative stress that can be selectively exploited by high-dose ascorbate [PMID:34127497, PMID:32152203]. Genetic dissection in mice shows that SDHB disruption alone produces succinate accumulation but not 5hmC loss, HIF accumulation, or tumors; frank pheochromocytoma requires cooperative loss of NF1 [PMID:35235785]. Biallelic SDHB loss also causes severe isolated complex II deficiency with leukodystrophy [PMID:22972948].","teleology":[{"year":2003,"claim":"Established SDHB as a two-hit tumor suppressor whose biallelic inactivation abolishes complex II activity and activates the hypoxic/angiogenic program, answering how an Fe-S subunit mutation predisposes to paraganglioma.","evidence":"Mutation/LOH analysis with respiratory chain enzyme assays and IHC/ISH on familial pheochromocytoma tumors","pmids":["11404820","12364472","14500403"],"confidence":"High","gaps":["Did not define how succinate accumulation links to the hypoxic program","Correlative pathway activation in tumor tissue, not mechanistic manipulation"]},{"year":2008,"claim":"Showed by direct knockdown that SDHB loss causes glycolytic shift, HIF-1α/HIF-2α stabilization, stress kinase activation, and altered ECM adhesion, moving from correlation to a causal cellular phenotype.","evidence":"siRNA knockdown with respirometry, microarray, adhesion assays and transient HIF-1α rescue","pmids":["18519664"],"confidence":"High","gaps":["HIF-1α silencing only partially reversed adhesion","Performed in a non-chromaffin cell context"]},{"year":2009,"claim":"Demonstrated that any SDH subunit mutation destabilizes the whole complex including SDHB, validating SDHB IHC as a surrogate for complex integrity.","evidence":"IHC on 220 tumors with known mutation status across multiple cohorts","pmids":["19576851"],"confidence":"High","gaps":["Did not resolve the molecular degradation pathway","Does not distinguish missense from truncating consequences"]},{"year":2012,"claim":"Resolved the protein-level basis of missense pathogenicity—accelerated degradation rather than catalytic impairment—while showing mutant SDHB retains localization and SDHA binding.","evidence":"Pulse-chase, co-IP, colocalization and HDAC-inhibitor rescue in transfected HeLa cells","pmids":["22835832"],"confidence":"High","gaps":["Did not identify the responsible E3/quality-control machinery","Used overexpression in a heterologous cell line"]},{"year":2012,"claim":"Linked SDHB mutation specifically to EMT activation in metastatic tumors, identifying a transcriptional invasion program.","evidence":"EMT-panel transcriptomics and Snail1/2 IHC on tumor cohorts; reciprocal KD/OE with SNAIL1-SMAD3/4 identification in colorectal cells","pmids":["22492777","27816688"],"confidence":"Medium","gaps":["Tumor data correlative without SDHB manipulation","SMAD3/4 mechanism shown in colorectal, not chromaffin, cells"]},{"year":2015,"claim":"Defined KRT19 epigenetic silencing as a downstream effector of SDHB-loss-driven invasiveness and confirmed the ROS→HIF1α→catecholamine axis.","evidence":"Sdhb-knockout chromaffin cells with KRT19 rescue/knockdown and bisulfite sequencing; PC12 knockdown with NAC and HIF1α rescue","pmids":["26460615","26620190"],"confidence":"High","gaps":["Direct link from succinate to KRT19 methylation not fully mapped","Catecholamine axis demonstrated in PC12 cells only"]},{"year":2016,"claim":"Pinpointed disruption of HSC20 binding to the LYR Fe-S transfer motif as the degradation trigger and characterized the metabolic state (succinate accumulation, reductive carboxylation, HIF1α, CIMP) of an SDHB-null line.","evidence":"Stable isotope-resolved metabolomics, co-chaperone binding assay and bioinformatics in an SDHB-deficient RCC line","pmids":["26719882"],"confidence":"High","gaps":["Single cell-line context","Did not determine why HIF1α rather than HIF2α dominates"]},{"year":2021,"claim":"Distinguished SDHB-specific consequences from SDHD loss, tying SDHB deficiency to iron/copper dysregulation, stronger hypermethylation, and selective ascorbate vulnerability.","evidence":"Comparative Sdhb vs Sdhd knockout chromaffin cells with metabolic, ROS and iron/copper assays plus ascorbate treatment; iron-transport protein analysis with in vivo allograft","pmids":["34127497","32152203"],"confidence":"Medium","gaps":["Mechanism of subunit-specific iron handling unresolved","Therapeutic ascorbate effect from single-lab models"]},{"year":2022,"claim":"Demonstrated by in vivo genetic epistasis that SDHB loss alone is insufficient for tumorigenesis and requires cooperative NF1 loss, refining the multi-hit tumor model.","evidence":"Conditional adrenal-medulla SDHB knockout and SDHB/NF1 double-knockout mouse models with ascorbate-depletion survival assay","pmids":["35235785"],"confidence":"High","gaps":["Why succinate accumulation alone fails to drive 5hmC loss/HIF in vivo unexplained","Other cooperating lesions beyond NF1 not surveyed"]},{"year":null,"claim":"It remains unresolved how succinate accumulation is mechanistically coupled to the specific epigenetic and metabolic vulnerabilities, and which protein quality-control machinery executes mutant SDHB degradation.","evidence":"","pmids":[],"confidence":"Medium","gaps":["E3 ligase/degradation pathway for mutant SDHB unidentified","Direct succinate-to-target dioxygenase epistasis not fully mapped","Cooperating drivers beyond NF1 uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2,3,7,9,17]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[5,7,21]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,10,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,4,16]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[3,9,11]}],"complexes":["Succinate dehydrogenase (mitochondrial complex II)"],"partners":["SDHA","HSC20","NF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21912","full_name":"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial","aliases":["Iron-sulfur subunit of complex II","Ip","Malate dehydrogenase [quinone] iron-sulfur subunit"],"length_aa":280,"mass_kda":31.6,"function":"Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:26925370, PubMed:27604842). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate (By similarity)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P21912/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SDHB","classification":"Not Classified","n_dependent_lines":581,"n_total_lines":1208,"dependency_fraction":0.48096026490066224},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HEATR3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/SDHB","total_profiled":1310},"omim":[{"mim_id":"619224","title":"MITOCHONDRIAL COMPLEX II DEFICIENCY, NUCLEAR TYPE 4; MC2DN4","url":"https://www.omim.org/entry/619224"},{"mim_id":"619219","title":"CHROMOSOME 2 OPEN READING FRAME 69; C2ORF69","url":"https://www.omim.org/entry/619219"},{"mim_id":"619198","title":"SUCCINATE DEHYDROGENASE COMPLEX ASSEMBLY FACTOR 4; SDHAF4","url":"https://www.omim.org/entry/619198"},{"mim_id":"617717","title":"AUDITORY NEUROPATHY AND OPTIC ATROPHY; ANOA","url":"https://www.omim.org/entry/617717"},{"mim_id":"615330","title":"MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 3; MMDS3","url":"https://www.omim.org/entry/615330"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":460.5},{"tissue":"tongue","ntpm":542.0}],"url":"https://www.proteinatlas.org/search/SDHB"},"hgnc":{"alias_symbol":[],"prev_symbol":["SDH1","SDH"]},"alphafold":{"accession":"P21912","domains":[{"cath_id":"3.10.20.30","chopping":"38-140","consensus_level":"high","plddt":98.4768,"start":38,"end":140},{"cath_id":"1.10.1060.10","chopping":"142-156_175-278","consensus_level":"high","plddt":96.8182,"start":142,"end":278}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21912","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21912-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21912-F1-predicted_aligned_error_v6.png","plddt_mean":91.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SDHB","jax_strain_url":"https://www.jax.org/strain/search?query=SDHB"},"sequence":{"accession":"P21912","fasta_url":"https://rest.uniprot.org/uniprotkb/P21912.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21912/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21912"}},"corpus_meta":[{"pmid":"11404820","id":"PMC_11404820","title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11404820","citation_count":885,"is_preprint":false},{"pmid":"15328326","id":"PMC_15328326","title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.","date":"2004","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/15328326","citation_count":736,"is_preprint":false},{"pmid":"14500403","id":"PMC_14500403","title":"Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14500403","citation_count":453,"is_preprint":false},{"pmid":"19576851","id":"PMC_19576851","title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.","date":"2009","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19576851","citation_count":424,"is_preprint":false},{"pmid":"17667967","id":"PMC_17667967","title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.","date":"2007","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/17667967","citation_count":353,"is_preprint":false},{"pmid":"22036874","id":"PMC_22036874","title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.","date":"2011","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/22036874","citation_count":283,"is_preprint":false},{"pmid":"19802898","id":"PMC_19802898","title":"Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19802898","citation_count":272,"is_preprint":false},{"pmid":"11897817","id":"PMC_11897817","title":"Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas.","date":"2002","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11897817","citation_count":270,"is_preprint":false},{"pmid":"18728283","id":"PMC_18728283","title":"Germline SDHB mutations and familial renal cell carcinoma.","date":"2008","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/18728283","citation_count":265,"is_preprint":false},{"pmid":"20236688","id":"PMC_20236688","title":"Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.","date":"2010","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20236688","citation_count":212,"is_preprint":false},{"pmid":"29386252","id":"PMC_29386252","title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29386252","citation_count":203,"is_preprint":false},{"pmid":"12364472","id":"PMC_12364472","title":"Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12364472","citation_count":182,"is_preprint":false},{"pmid":"24752622","id":"PMC_24752622","title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24752622","citation_count":162,"is_preprint":false},{"pmid":"32012263","id":"PMC_32012263","title":"Trimethylamine N-oxide promotes apoE-/- mice atherosclerosis by inducing vascular endothelial cell pyroptosis via the SDHB/ROS pathway.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32012263","citation_count":120,"is_preprint":false},{"pmid":"23099648","id":"PMC_23099648","title":"Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis.","date":"2012","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23099648","citation_count":113,"is_preprint":false},{"pmid":"26719882","id":"PMC_26719882","title":"SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery.","date":"2016","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/26719882","citation_count":97,"is_preprint":false},{"pmid":"22972948","id":"PMC_22972948","title":"Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency.","date":"2012","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22972948","citation_count":96,"is_preprint":false},{"pmid":"17599579","id":"PMC_17599579","title":"Malignant head and neck paragangliomas in SDHB mutation carriers.","date":"2007","source":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/17599579","citation_count":94,"is_preprint":false},{"pmid":"12618761","id":"PMC_12618761","title":"Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12618761","citation_count":94,"is_preprint":false},{"pmid":"22492777","id":"PMC_22492777","title":"Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22492777","citation_count":93,"is_preprint":false},{"pmid":"14974914","id":"PMC_14974914","title":"Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.","date":"2003","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14974914","citation_count":86,"is_preprint":false},{"pmid":"16405730","id":"PMC_16405730","title":"Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.","date":"2006","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16405730","citation_count":86,"is_preprint":false},{"pmid":"38097671","id":"PMC_38097671","title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.","date":"2023","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38097671","citation_count":85,"is_preprint":false},{"pmid":"24168041","id":"PMC_24168041","title":"Fitness and competitive ability of Botrytis cinerea field isolates with dual resistance to SDHI and QoI fungicides, associated with several sdhB and the cytb G143A mutations.","date":"2014","source":"Phytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24168041","citation_count":83,"is_preprint":false},{"pmid":"18519664","id":"PMC_18519664","title":"Cells silenced for SDHB expression display characteristic features of the tumor phenotype.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18519664","citation_count":81,"is_preprint":false},{"pmid":"28374168","id":"PMC_28374168","title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.","date":"2017","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28374168","citation_count":71,"is_preprint":false},{"pmid":"29636359","id":"PMC_29636359","title":"Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29636359","citation_count":68,"is_preprint":false},{"pmid":"27839933","id":"PMC_27839933","title":"SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.","date":"2016","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/27839933","citation_count":65,"is_preprint":false},{"pmid":"20503330","id":"PMC_20503330","title":"Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20503330","citation_count":61,"is_preprint":false},{"pmid":"31299266","id":"PMC_31299266","title":"Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.","date":"2019","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31299266","citation_count":60,"is_preprint":false},{"pmid":"27816688","id":"PMC_27816688","title":"SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4.","date":"2016","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27816688","citation_count":60,"is_preprint":false},{"pmid":"23109135","id":"PMC_23109135","title":"Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.","date":"2012","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23109135","citation_count":60,"is_preprint":false},{"pmid":"23072324","id":"PMC_23072324","title":"Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma.","date":"2013","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23072324","citation_count":59,"is_preprint":false},{"pmid":"28503760","id":"PMC_28503760","title":"The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers.","date":"2017","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28503760","citation_count":58,"is_preprint":false},{"pmid":"34127497","id":"PMC_34127497","title":"Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34127497","citation_count":58,"is_preprint":false},{"pmid":"25048685","id":"PMC_25048685","title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25048685","citation_count":58,"is_preprint":false},{"pmid":"22241719","id":"PMC_22241719","title":"The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.","date":"2012","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22241719","citation_count":57,"is_preprint":false},{"pmid":"26460615","id":"PMC_26460615","title":"Deciphering the molecular basis of invasiveness in Sdhb-deficient cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26460615","citation_count":57,"is_preprint":false},{"pmid":"15220362","id":"PMC_15220362","title":"Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.","date":"2004","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15220362","citation_count":57,"is_preprint":false},{"pmid":"33248263","id":"PMC_33248263","title":"Low shear stress induced vascular endothelial cell pyroptosis by TET2/SDHB/ROS pathway.","date":"2020","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33248263","citation_count":56,"is_preprint":false},{"pmid":"1511876","id":"PMC_1511876","title":"SDH1, the gene encoding the succinate dehydrogenase flavoprotein subunit from Saccharomyces cerevisiae.","date":"1992","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/1511876","citation_count":52,"is_preprint":false},{"pmid":"20702724","id":"PMC_20702724","title":"SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20702724","citation_count":52,"is_preprint":false},{"pmid":"24169168","id":"PMC_24169168","title":"The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas.","date":"2014","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24169168","citation_count":50,"is_preprint":false},{"pmid":"22835832","id":"PMC_22835832","title":"Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22835832","citation_count":47,"is_preprint":false},{"pmid":"20592014","id":"PMC_20592014","title":"Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20592014","citation_count":46,"is_preprint":false},{"pmid":"20540712","id":"PMC_20540712","title":"Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20540712","citation_count":45,"is_preprint":false},{"pmid":"22261759","id":"PMC_22261759","title":"Elevated plasma succinate in PTEN, SDHB, and SDHD mutation-positive individuals.","date":"2012","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22261759","citation_count":43,"is_preprint":false},{"pmid":"32061949","id":"PMC_32061949","title":"Melatonin alleviates progression of uterine endometrial cancer by suppressing estrogen/ubiquitin C/SDHB-mediated succinate accumulation.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32061949","citation_count":42,"is_preprint":false},{"pmid":"28622713","id":"PMC_28622713","title":"miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28622713","citation_count":42,"is_preprint":false},{"pmid":"32152203","id":"PMC_32152203","title":"Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32152203","citation_count":41,"is_preprint":false},{"pmid":"32062700","id":"PMC_32062700","title":"Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.","date":"2020","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32062700","citation_count":40,"is_preprint":false},{"pmid":"28490599","id":"PMC_28490599","title":"The phenotype of SDHB germline mutation carriers: a nationwide study.","date":"2017","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28490599","citation_count":40,"is_preprint":false},{"pmid":"29079178","id":"PMC_29079178","title":"The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.","date":"2017","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29079178","citation_count":40,"is_preprint":false},{"pmid":"15505628","id":"PMC_15505628","title":"Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15505628","citation_count":39,"is_preprint":false},{"pmid":"25376524","id":"PMC_25376524","title":"Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.","date":"2014","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25376524","citation_count":39,"is_preprint":false},{"pmid":"26113606","id":"PMC_26113606","title":"15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.","date":"2015","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26113606","citation_count":38,"is_preprint":false},{"pmid":"15883710","id":"PMC_15883710","title":"Mutations of the SDHB and SDHD genes.","date":"2005","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15883710","citation_count":36,"is_preprint":false},{"pmid":"21479127","id":"PMC_21479127","title":"Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of Gists.","date":"2011","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21479127","citation_count":35,"is_preprint":false},{"pmid":"34094922","id":"PMC_34094922","title":"SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34094922","citation_count":34,"is_preprint":false},{"pmid":"35235785","id":"PMC_35235785","title":"SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35235785","citation_count":33,"is_preprint":false},{"pmid":"19208735","id":"PMC_19208735","title":"Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.","date":"2009","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19208735","citation_count":33,"is_preprint":false},{"pmid":"22948026","id":"PMC_22948026","title":"High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations.","date":"2012","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/22948026","citation_count":31,"is_preprint":false},{"pmid":"19368708","id":"PMC_19368708","title":"The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19368708","citation_count":31,"is_preprint":false},{"pmid":"30769052","id":"PMC_30769052","title":"γ-Tocotrienol inhibits oxidative phosphorylation and triggers apoptosis by inhibiting mitochondrial complex I subunit NDUFB8 and complex II subunit SDHB.","date":"2019","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30769052","citation_count":30,"is_preprint":false},{"pmid":"27573198","id":"PMC_27573198","title":"Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers.","date":"2017","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27573198","citation_count":29,"is_preprint":false},{"pmid":"26620190","id":"PMC_26620190","title":"Loss of SDHB Elevates Catecholamine Synthesis and Secretion Depending on ROS Production and HIF Stabilization.","date":"2015","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/26620190","citation_count":29,"is_preprint":false},{"pmid":"28830936","id":"PMC_28830936","title":"The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28830936","citation_count":29,"is_preprint":false},{"pmid":"31979226","id":"PMC_31979226","title":"Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31979226","citation_count":28,"is_preprint":false},{"pmid":"32252027","id":"PMC_32252027","title":"A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32252027","citation_count":27,"is_preprint":false},{"pmid":"24058882","id":"PMC_24058882","title":"Hypoxia-inducible C-to-U coding RNA editing downregulates SDHB in monocytes.","date":"2013","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/24058882","citation_count":26,"is_preprint":false},{"pmid":"36657474","id":"PMC_36657474","title":"Resistance Risk and Resistance-Related Point Mutation in SdhB and SdhC1 of Cyclobutrifluram in Fusarium pseudograminearum.","date":"2023","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36657474","citation_count":25,"is_preprint":false},{"pmid":"17102086","id":"PMC_17102086","title":"Paraganglioma syndrome: SDHB, SDHC, and SDHD mutations in head and neck paragangliomas.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17102086","citation_count":24,"is_preprint":false},{"pmid":"31492822","id":"PMC_31492822","title":"Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma.","date":"2019","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31492822","citation_count":24,"is_preprint":false},{"pmid":"30159755","id":"PMC_30159755","title":"Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells.","date":"2018","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/30159755","citation_count":24,"is_preprint":false},{"pmid":"33098218","id":"PMC_33098218","title":"Heterokaryotic state of a point mutation (H249Y) in SDHB protein drives the evolution of thifluzamide resistance in Rhizoctonia solani.","date":"2020","source":"Pest management science","url":"https://pubmed.ncbi.nlm.nih.gov/33098218","citation_count":23,"is_preprint":false},{"pmid":"29180251","id":"PMC_29180251","title":"Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex.","date":"2017","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29180251","citation_count":23,"is_preprint":false},{"pmid":"28456312","id":"PMC_28456312","title":"Characterization of boscalid-resistance conferring mutations in the SdhB subunit of respiratory complex II and impact on fitness and mycotoxin production in Penicillium expansum laboratory strains.","date":"2017","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28456312","citation_count":23,"is_preprint":false},{"pmid":"15479192","id":"PMC_15479192","title":"SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas.","date":"2004","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15479192","citation_count":22,"is_preprint":false},{"pmid":"35172488","id":"PMC_35172488","title":"Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal SDHB-Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.","date":"2017","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35172488","citation_count":22,"is_preprint":false},{"pmid":"40097403","id":"PMC_40097403","title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40097403","citation_count":21,"is_preprint":false},{"pmid":"25808177","id":"PMC_25808177","title":"Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function.","date":"2015","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25808177","citation_count":21,"is_preprint":false},{"pmid":"30352407","id":"PMC_30352407","title":"Germline SDHB and SDHD mutations in pheochromocytoma and paraganglioma patients.","date":"2018","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/30352407","citation_count":20,"is_preprint":false},{"pmid":"35008989","id":"PMC_35008989","title":"Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35008989","citation_count":20,"is_preprint":false},{"pmid":"32150977","id":"PMC_32150977","title":"Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32150977","citation_count":20,"is_preprint":false},{"pmid":"30658386","id":"PMC_30658386","title":"Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30658386","citation_count":20,"is_preprint":false},{"pmid":"25808178","id":"PMC_25808178","title":"Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria.","date":"2015","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25808178","citation_count":20,"is_preprint":false},{"pmid":"28099933","id":"PMC_28099933","title":"Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28099933","citation_count":20,"is_preprint":false},{"pmid":"29930107","id":"PMC_29930107","title":"An Assembly Factor Promotes Assembly of Flavinated SDH1 into the Succinate Dehydrogenase Complex.","date":"2018","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29930107","citation_count":19,"is_preprint":false},{"pmid":"37734265","id":"PMC_37734265","title":"Research progress on the pathogenesis of the SDHB mutation and related diseases.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37734265","citation_count":18,"is_preprint":false},{"pmid":"30934121","id":"PMC_30934121","title":"Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study.","date":"2019","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30934121","citation_count":18,"is_preprint":false},{"pmid":"15473885","id":"PMC_15473885","title":"K40E: a novel succinate dehydrogenase (SDH)B mutation causing familial phaeochromocytoma and paraganglioma.","date":"2004","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15473885","citation_count":18,"is_preprint":false},{"pmid":"27604842","id":"PMC_27604842","title":"Leukoencephalopathy due to Complex II Deficiency and Bi-Allelic SDHB Mutations: Further Cases and Implications for Genetic Counselling.","date":"2016","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/27604842","citation_count":18,"is_preprint":false},{"pmid":"25371406","id":"PMC_25371406","title":"Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25371406","citation_count":17,"is_preprint":false},{"pmid":"34750193","id":"PMC_34750193","title":"SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma.","date":"2021","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34750193","citation_count":16,"is_preprint":false},{"pmid":"35546442","id":"PMC_35546442","title":"An exploration in pitfalls in interpreting SDHB immunohistochemistry.","date":"2022","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/35546442","citation_count":16,"is_preprint":false},{"pmid":"31749660","id":"PMC_31749660","title":"MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31749660","citation_count":16,"is_preprint":false},{"pmid":"36455002","id":"PMC_36455002","title":"Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36455002","citation_count":16,"is_preprint":false},{"pmid":"17308434","id":"PMC_17308434","title":"Novel germline mutations in the SDHB and SDHD genes in Japanese pheochromocytomas.","date":"2007","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/17308434","citation_count":16,"is_preprint":false},{"pmid":"33156815","id":"PMC_33156815","title":"Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33156815","citation_count":15,"is_preprint":false},{"pmid":"16491957","id":"PMC_16491957","title":"There is no evidence that the SDHB gene is involved in neuroblastoma development.","date":"2005","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/16491957","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56019,"output_tokens":5869,"usd":0.128046,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14717,"output_tokens":3517,"usd":0.080755,"stage2_stop_reason":"end_turn"},"total_usd":0.208801,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Inactivating germline SDHB mutations cause loss of complex II catalytic activity, establishing SDHB as part of the catalytic core of succinate dehydrogenase (mitochondrial complex II) and a tumor suppressor gene whose disruption predisposes to pheochromocytoma and paraganglioma.\",\n      \"method\": \"Mutation analysis (sequencing) of familial pheochromocytoma kindreds; functional context from known complex II biochemistry\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mutation identification in familial cases with biochemical context; single study but clear loss-of-function result\",\n      \"pmids\": [\"11404820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A germline SDHB missense mutation combined with somatic loss of heterozygosity at 1p36 (SDHB locus) resulted in complete loss of mitochondrial complex II enzymatic activity in a pheochromocytoma, accompanied by upregulation of hypoxia-angiogenic responsive genes (pseudohypoxia), demonstrating that biallelic SDHB inactivation abolishes complex II function and activates the hypoxic/angiogenic pathway.\",\n      \"method\": \"LOH analysis, respiratory chain enzyme assay, in situ hybridization, immunohistochemistry on tumor tissue\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct enzyme activity assay confirming complete loss of complex II activity, combined with LOH analysis and IHC/ISH for pathway activation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"12364472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Deleterious SDHB germline mutations in pheochromocytoma are associated with complete loss of complex II catalytic activity in tumor tissue and LOH at chromosome 1p36 (SDHB locus), confirming SDHB as a tumor suppressor following a two-hit mechanism.\",\n      \"method\": \"Respiratory chain enzyme assay, LOH analysis, immunohistochemistry on tumor samples\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct enzyme activity assays combined with LOH and IHC; replicated findings from prior work with larger cohort\",\n      \"pmids\": [\"14500403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SDHB silencing by DNA-based siRNA impaired cellular respiration, caused a shift to glycolysis, upregulated HIF-1α and HIF-2α (pseudohypoxia), hyperphosphorylated JNK and p38 stress kinases, and increased cell adhesion to extracellular matrix components (fibronectin, laminin); partial reversal of the adhesion phenotype by transient HIF-1α silencing implicated HIF-1 in this process.\",\n      \"method\": \"RNA interference (siRNA knockdown), respirometry, microarray, Western blot, cell adhesion assay, transient HIF-1α knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with multiple orthogonal readouts (respiration, ROS, gene expression, adhesion, rescue experiment); single lab\",\n      \"pmids\": [\"18519664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SDHB protein expression is absent by immunohistochemistry in tumors harboring SDHB, SDHC, or SDHD mutations but is retained in tumors from MEN2, VHL, and NF1 patients, demonstrating that loss of any SDH subunit destabilizes the whole complex including the SDHB subunit, making SDHB IHC a surrogate marker for SDH complex integrity.\",\n      \"method\": \"Immunohistochemistry on 220 tumors with known mutation status (retrospective and prospective series)\",\n      \"journal\": \"The Lancet. Oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large prospective and retrospective series with known mutation status; independently replicated across multiple cohorts\",\n      \"pmids\": [\"19576851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Common SDHB missense mutations do not impair mRNA expression or intrinsic enzymatic function, but reduce protein half-life (accelerated degradation), demonstrated by pulse-chase assay; the mutant SDHB protein retains correct mitochondrial localization and the ability to co-immunoprecipitate with SDHA, indicating complex formation is intact. Treatment with HDAC inhibitors extended mutant protein half-life, implicating the protein quality control machinery in SDHB degradation.\",\n      \"method\": \"Pulse-chase assay in transfected HeLa cells, RT-PCR, Western blot, subcellular colocalization, co-immunoprecipitation, HDAC inhibitor treatment\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstitution-type in vitro pulse-chase with mutagenesis context, co-IP and colocalization, pharmacological rescue; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"22835832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SDHB mutations are associated with activation of epithelial-to-mesenchymal transition (EMT) in metastatic pheochromocytomas/paragangliomas, evidenced by upregulation of LOXL2, TWIST, TCF3, MMP2, MMP1 and downregulation of KRT19 and CDH2, with nuclear translocation of Snail1/2 specifically in SDHB-mutated metastatic tumors.\",\n      \"method\": \"Transcriptomic profiling of 188 tumor samples (94-gene EMT panel), immunohistochemistry (Snail1/2) in 93 tumors\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — large transcriptomic dataset with IHC validation; single lab, correlative rather than experimental manipulation of SDHB\",\n      \"pmids\": [\"22492777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Homozygous SDHB mutation (p.Asp48Val) in a patient causes severe isolated mitochondrial complex II deficiency with hypotonia and leukodystrophy; Western blot and BN-PAGE confirmed decreased steady-state SDHB protein and impaired complex II assembly; yeast complementation studies confirmed pathogenicity.\",\n      \"method\": \"Western blot, BN-PAGE, enzyme activity assay, yeast complementation\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct enzyme activity, protein assembly assays, and yeast complementation functional validation; single report but multiple orthogonal methods\",\n      \"pmids\": [\"22972948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In Sdhb-knockout mouse chromaffin cells, loss of SDHB produced increased individual cell migration (faster motility, increased persistence), invasiveness, and adhesion; this phenotype was associated with epigenetic silencing (hypermethylation) of Krt19 and EMT-like reprogramming (modulation of Twist1, Twist2, Tcf3, Snai1, N-cadherin). KRT19 rescue by lentiviral transduction reduced invasion, and KRT19 knockdown in wild-type cells increased invasion, establishing KRT19 as a downstream effector of SDHB loss-driven invasiveness.\",\n      \"method\": \"Sdhb knockout in mouse chromaffin cells, migration/invasion assays, lentiviral KRT19 rescue, siRNA KRT19 knockdown, bisulfite sequencing, demethylating agent treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with functional rescue and knockdown experiments using multiple orthogonal methods; single lab\",\n      \"pmids\": [\"26460615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SDHB silencing in PC12 pheochromocytoma cells abolishes complex II activity, increases ROS production and stabilizes nuclear HIF1α under normoxia; these effects increase tyrosine hydroxylase activity and catecholamine secretion. Pretreatment with NAC (ROS scavenger) or HIF1α knockdown abolishes these phenotypes, establishing an ROS→HIF1α→catecholamine axis downstream of SDHB loss.\",\n      \"method\": \"siRNA knockdown in PC12 cells, complex II activity assay, ROS measurement, catecholamine secretion assay, NAC treatment, HIF1α siRNA rescue\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic assay + ROS measurement + pharmacological and genetic rescue experiments; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26620190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The SDHB R46Q mutation in an SDHB-deficient renal cell carcinoma line (UOK269) disrupts binding of the cochaperone HSC20 to the L(I)YR Fe-S transfer motif in SDHB, causing rapid SDHB degradation and loss of SDH activity. In the absence of SDHB, succinate accumulates (351.4 ± 63.2 nmol/mg), respiration is undetectable, glutamine becomes the main TCA substrate via reductive carboxylation, HIF1α (not HIF2α) increases, and a CpG island methylator phenotype (CIMP) develops. Bioinformatic screening showed 37% of disease-causing SDHB missense mutations affect LYR Fe-S transfer motifs or Fe-S cluster-ligating cysteines.\",\n      \"method\": \"Stable isotope-resolved metabolomics, biochemical co-chaperone binding assay, respiration assay, Western blot, bioinformatics in novel SDHB-deficient RCC cell line\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstitution-level metabolomics and biochemical assays in a defined SDHB-null cell line, with Fe-S chaperone binding mechanism identified; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26719882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SDHB mRNA undergoes C-to-U coding RNA editing (C136U, R46X) in peripheral blood monocytes; this editing is markedly upregulated by hypoxia (1% O2) and during macrophage differentiation, representing an epigenetic post-transcriptional mechanism that downregulates SDHB function in monocytes during hypoxia adaptation. CD14-positive monocytes are the principal editing cell type; CD14-negative lymphocytes show no editing.\",\n      \"method\": \"Allele-specific quantitative PCR, flow cytometry, immunologic cell separation, gene expression microarray, high-throughput RNA sequencing, hypoxia exposure experiments\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel mechanism identified with multiple orthogonal methods (qPCR, RNA-seq, cell fractionation, hypoxia experiments); single lab\",\n      \"pmids\": [\"24058882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SDHB deficiency in colorectal cancer cells promotes cell migration and invasion through EMT enabled by upregulation of the transcriptional repression complex SNAIL1-SMAD3/SMAD4, activating TGFβ signaling. SDHB knockdown increased migration/invasion, while SDHB overexpression reversed this; SNAIL1-SMAD3/SMAD4 was identified as the downstream mediator.\",\n      \"method\": \"siRNA knockdown, overexpression, transwell migration/invasion assays, Western blot, pathway analysis in colorectal cancer cells\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD and OE with reciprocal phenotype plus pathway identification; single lab\",\n      \"pmids\": [\"27816688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TET2 loss (induced by low shear stress) upregulates SDHB expression and activity by decreasing recruitment of histone deacetylase 2 to the SDHB promoter (independent of DNA demethylation), leading to SDHB-mediated mitochondrial injury, increased ROS, and vascular endothelial cell pyroptosis; ROS scavenger NAC rescued pyroptosis, placing SDHB downstream of TET2 in a TET2/SDHB/ROS pathway.\",\n      \"method\": \"TET2 shRNA, SDHB overexpression, NAC treatment, HDAC2 recruitment assay, mitochondrial ROS measurement, pyroptosis assay in HUVECs\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological intervention with mechanistic epistasis; single lab\",\n      \"pmids\": [\"33248263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SDHB overexpression in endothelial cells enhances pyroptosis and mitochondrial ROS production; this effect is blocked by the ROS scavenger NAC, establishing that SDHB-driven ROS mediates endothelial cell pyroptosis in the context of TMAO-induced atherosclerosis.\",\n      \"method\": \"SDHB overexpression in HUVECs, NAC treatment, ROS assay, pyroptosis assay, apoE-/- mouse model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with pharmacological rescue showing ROS dependence; single lab\",\n      \"pmids\": [\"32012263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of SDHB specifically (compared to SDHD loss) leads to dysregulated iron and copper homeostasis, increased oxidative stress, and hallmarks of mesenchymal transition associated with stronger DNA hypermethylation and pseudo-hypoxic phenotype, without NRF2 activation. High-dose ascorbate exacerbated mitochondrial ROS selectively in Sdhb-deficient cells, causing cell death, establishing a mechanistic link between SDHB loss, iron overload, and ROS accumulation distinct from SDHD loss.\",\n      \"method\": \"Sdhb and Sdhd knockout chromaffin cell lines, metabolic analysis, ROS assay, iron/copper homeostasis measurements, ascorbate treatment, comparative SDHB vs SDHD cell analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — comparative KO models with multiple metabolic and functional assays, pharmacological intervention; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34127497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mouse adrenal medulla-specific SDHB disruption recapitulates succinate accumulation but does NOT cause 5hmC loss, HIF accumulation, or tumorigenesis on its own. Concomitant SDHB and NF1 disruption yields SDHx-like pheochromocytomas, demonstrating that SDHB loss requires additional growth-regulatory pathway activation (NF1 loss) for tumorigenesis. In vitro, 2-OG dioxygenase cofactor ascorbate depletion reduces SDHB-deficient cell survival.\",\n      \"method\": \"Conditional mouse SDHB knockout, double SDHB/NF1 knockout mouse model, in vivo tumor analysis, ascorbate depletion cell survival assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis with double KO model plus in vitro mechanistic follow-up; single study but rigorous genetic approach with clear negative and positive results\",\n      \"pmids\": [\"35235785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of sdhb in zebrafish larvae (CRISPR/cas9 truncating mutation) decreases mitochondrial complex II activity and causes significant succinate accumulation, recapitulating the metabolic phenotype of human SDHB-associated paragangliomas in a vertebrate model.\",\n      \"method\": \"CRISPR/cas9 zebrafish knockout, complex II enzymatic activity assay, metabolomic analysis (succinate measurement), behavioral and morphological phenotyping\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct enzymatic assay and metabolomics in an in vivo genetic model; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"33156815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SDHB germline mutations in metastatic pheochromocytoma/paraganglioma are associated with hypermethylation of the MGMT promoter and low MGMT expression, which correlates with responsiveness to temozolomide chemotherapy; partial responses to TMZ were observed only in SDHB-mutated patients.\",\n      \"method\": \"Retrospective clinical study, MGMT immunohistochemistry, MGMT promoter methylation analysis in 190 PPGLs, survival/response analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic link between SDHB mutation status and MGMT methylation established in large tumor cohort with clinical correlation; single study\",\n      \"pmids\": [\"24752622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SDHB-deficient pheochromocytoma cells (with pseudohypoxia from SDHB loss) display elevated expression of iron transport proteins (transferrin, TFR2, DMT1/SLC11A2), leading to iron accumulation and elevated oxidative stress; pharmacological ascorbic acid disrupts redox homeostasis, induces DNA oxidative damage and apoptosis selectively in SDHB-low cells, and suppresses metastatic lesions in a mouse allograft model.\",\n      \"method\": \"Western blot for iron transport proteins, ROS/oxidative stress assays, ascorbic acid treatment in vitro and in vivo (mouse allograft model), survival analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanism linked to iron transport protein upregulation with in vitro and in vivo validation; single lab\",\n      \"pmids\": [\"32152203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SDHB-deficient cluster I PCPGs develop dependency on mitochondrial complex I and enhanced NAD+ metabolism; this supports chemoresistance via the PARP1/BER DNA repair pathway. Combining a PARP inhibitor with temozolomide improved cytotoxicity, reduced metastatic lesions, and prolonged survival in mice with SDHB-knockdown PCPG allografts.\",\n      \"method\": \"Transcriptomic profiling of clinical specimens, PARP inhibitor + TMZ combination in vitro and in vivo (mouse allograft), NAD+ pathway analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway identification from clinical specimens with in vivo pharmacological validation; single lab\",\n      \"pmids\": [\"29636359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Carney triad tumors and Sdhb+/- mouse gastrointestinal tissues share an identical mitochondrial structural phenotype (loss of cristae, structural abnormalities, variable size) with SDH-deficient tumors, establishing that SDHB haploinsufficiency is sufficient to produce abnormal mitochondrial morphology (hypoxic mitochondrial phenotype) in vivo.\",\n      \"method\": \"Electron microscopy of human tumors (CTr, CSS, isolated GIST) and Sdhb+/- mouse GI tissue\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ultrastructural comparison of genetic model with human tumor tissue; single study with clear morphological data\",\n      \"pmids\": [\"25808178\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SDHB encodes the iron-sulfur subunit of mitochondrial complex II (succinate dehydrogenase); biallelic loss abolishes complex II enzymatic activity, causing succinate accumulation that inhibits 2-oxoglutarate-dependent dioxygenases (driving DNA/histone hypermethylation and pseudohypoxia via HIF stabilization), while disease-causing missense mutations primarily destabilize the protein by disrupting HSC20-mediated Fe-S cluster delivery or accelerating proteasomal degradation without intrinsically impairing enzymatic activity; downstream consequences of SDHB loss include ROS-mediated HIF1α stabilization, iron homeostasis dysregulation, EMT-like transcriptional reprogramming (via SNAIL1-SMAD3/4 and epigenetic KRT19 silencing), increased cell invasiveness and collective migration, and—requiring cooperative loss of additional tumor suppressors such as NF1—frank tumorigenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SDHB encodes the iron-sulfur subunit of mitochondrial complex II (succinate dehydrogenase), and its inactivation defines a tumor-suppressor mechanism in which loss of complex II catalytic activity drives succinate accumulation and a pseudohypoxic transcriptional program [#0, #1, #2]. Biallelic inactivation—a germline mutation plus somatic loss of heterozygosity at the 1p36 SDHB locus—abolishes complex II enzymatic activity and upregulates hypoxia-angiogenic responsive genes [#1, #2]. Loss of SDHB destabilizes the entire SDH complex such that the SDHB protein becomes undetectable by immunohistochemistry, making it a surrogate marker of complex integrity [#4]. At the protein level, common disease-causing missense mutations do not impair intrinsic enzymatic function or complex assembly but accelerate proteasomal degradation, frequently by disrupting binding of the cochaperone HSC20 to the L(I)YR Fe-S transfer motif, thereby blocking iron-sulfur cluster delivery [#5, #10]. SDHB loss reprograms cell metabolism toward glycolysis and reductive glutamine carboxylation, raises mitochondrial ROS, and stabilizes HIF1\\u03b1 under normoxia, an axis that in chromaffin cells elevates catecholamine secretion [#3, #9, #10]. Succinate accumulation and associated DNA/histone hypermethylation underlie a CpG island methylator phenotype, including epigenetic silencing of KRT19, and an EMT-like program—via nuclear Snail1/2 and a SNAIL1-SMAD3/4 repressor complex—that promotes invasion and migration [#6, #8, #10, #12]. SDHB loss also dysregulates iron and copper homeostasis, generating oxidative stress that can be selectively exploited by high-dose ascorbate [#15, #19]. Genetic dissection in mice shows that SDHB disruption alone produces succinate accumulation but not 5hmC loss, HIF accumulation, or tumors; frank pheochromocytoma requires cooperative loss of NF1 [#16]. Biallelic SDHB loss also causes severe isolated complex II deficiency with leukodystrophy [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established SDHB as a two-hit tumor suppressor whose biallelic inactivation abolishes complex II activity and activates the hypoxic/angiogenic program, answering how an Fe-S subunit mutation predisposes to paraganglioma.\",\n      \"evidence\": \"Mutation/LOH analysis with respiratory chain enzyme assays and IHC/ISH on familial pheochromocytoma tumors\",\n      \"pmids\": [\"11404820\", \"12364472\", \"14500403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how succinate accumulation links to the hypoxic program\", \"Correlative pathway activation in tumor tissue, not mechanistic manipulation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed by direct knockdown that SDHB loss causes glycolytic shift, HIF-1\\u03b1/HIF-2\\u03b1 stabilization, stress kinase activation, and altered ECM adhesion, moving from correlation to a causal cellular phenotype.\",\n      \"evidence\": \"siRNA knockdown with respirometry, microarray, adhesion assays and transient HIF-1\\u03b1 rescue\",\n      \"pmids\": [\"18519664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HIF-1\\u03b1 silencing only partially reversed adhesion\", \"Performed in a non-chromaffin cell context\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated that any SDH subunit mutation destabilizes the whole complex including SDHB, validating SDHB IHC as a surrogate for complex integrity.\",\n      \"evidence\": \"IHC on 220 tumors with known mutation status across multiple cohorts\",\n      \"pmids\": [\"19576851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the molecular degradation pathway\", \"Does not distinguish missense from truncating consequences\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved the protein-level basis of missense pathogenicity—accelerated degradation rather than catalytic impairment—while showing mutant SDHB retains localization and SDHA binding.\",\n      \"evidence\": \"Pulse-chase, co-IP, colocalization and HDAC-inhibitor rescue in transfected HeLa cells\",\n      \"pmids\": [\"22835832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the responsible E3/quality-control machinery\", \"Used overexpression in a heterologous cell line\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked SDHB mutation specifically to EMT activation in metastatic tumors, identifying a transcriptional invasion program.\",\n      \"evidence\": \"EMT-panel transcriptomics and Snail1/2 IHC on tumor cohorts; reciprocal KD/OE with SNAIL1-SMAD3/4 identification in colorectal cells\",\n      \"pmids\": [\"22492777\", \"27816688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tumor data correlative without SDHB manipulation\", \"SMAD3/4 mechanism shown in colorectal, not chromaffin, cells\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined KRT19 epigenetic silencing as a downstream effector of SDHB-loss-driven invasiveness and confirmed the ROS\\u2192HIF1\\u03b1\\u2192catecholamine axis.\",\n      \"evidence\": \"Sdhb-knockout chromaffin cells with KRT19 rescue/knockdown and bisulfite sequencing; PC12 knockdown with NAC and HIF1\\u03b1 rescue\",\n      \"pmids\": [\"26460615\", \"26620190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link from succinate to KRT19 methylation not fully mapped\", \"Catecholamine axis demonstrated in PC12 cells only\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Pinpointed disruption of HSC20 binding to the LYR Fe-S transfer motif as the degradation trigger and characterized the metabolic state (succinate accumulation, reductive carboxylation, HIF1\\u03b1, CIMP) of an SDHB-null line.\",\n      \"evidence\": \"Stable isotope-resolved metabolomics, co-chaperone binding assay and bioinformatics in an SDHB-deficient RCC line\",\n      \"pmids\": [\"26719882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single cell-line context\", \"Did not determine why HIF1\\u03b1 rather than HIF2\\u03b1 dominates\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Distinguished SDHB-specific consequences from SDHD loss, tying SDHB deficiency to iron/copper dysregulation, stronger hypermethylation, and selective ascorbate vulnerability.\",\n      \"evidence\": \"Comparative Sdhb vs Sdhd knockout chromaffin cells with metabolic, ROS and iron/copper assays plus ascorbate treatment; iron-transport protein analysis with in vivo allograft\",\n      \"pmids\": [\"34127497\", \"32152203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of subunit-specific iron handling unresolved\", \"Therapeutic ascorbate effect from single-lab models\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated by in vivo genetic epistasis that SDHB loss alone is insufficient for tumorigenesis and requires cooperative NF1 loss, refining the multi-hit tumor model.\",\n      \"evidence\": \"Conditional adrenal-medulla SDHB knockout and SDHB/NF1 double-knockout mouse models with ascorbate-depletion survival assay\",\n      \"pmids\": [\"35235785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why succinate accumulation alone fails to drive 5hmC loss/HIF in vivo unexplained\", \"Other cooperating lesions beyond NF1 not surveyed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how succinate accumulation is mechanistically coupled to the specific epigenetic and metabolic vulnerabilities, and which protein quality-control machinery executes mutant SDHB degradation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase/degradation pathway for mutant SDHB unidentified\", \"Direct succinate-to-target dioxygenase epistasis not fully mapped\", \"Cooperating drivers beyond NF1 uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2, 3, 7, 9, 17]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [5, 7, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 10, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 4, 16]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [3, 9, 11]}\n    ],\n    \"complexes\": [\"Succinate dehydrogenase (mitochondrial complex II)\"],\n    \"partners\": [\"SDHA\", \"HSC20\", \"NF1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":9,"faith_total":9,"faith_pct":100.0}}